Halozyme Therapeutics in (halo 1 08/15/28)
13F holders, Q2 2025 (June 30)9holders −1
0new positions
1sold out
$1.14avg. 13F price*
At the end of Q2 2025, 9 institutions reported holding Halozyme Therapeutics in (halo 1 08/15/28) in their 13F filings, down 1 from Q1 2025. 0 opened new positions and 1 sold out. The largest holders were Absolute Investment Advisers, LLC ($15.9M), Ofi Invest Asset Management ($7.2M) and Sonora Investment Management Group, LLC ($2.6M).
- Company
- Halozyme Therapeutics in (halo 1 08/15/28)
- CUSIP
- 40637HAF6
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $14.4M |
All 13F filers, Q1 2025 → Q2 2025: 2,000,000 shares bought and 11,669,735 shares sold, net −9,669,735 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| Absolute Investment Advisers, LLC | 1.97% | Add +16.7% | 14,000,000 | $15.9M |
| Ofi Invest Asset Management | 0.18% | No change | 7,400,000 | $7.2M |
| Sonora Investment Management Group, LLC | 0.19% | Reduce -0.4% | 2,265,000 | $2.6M |
| Nomura Holdings Inc. | 0.01% | Reduce -74.7% | 19,846 | $1.0M |
| Bank of New York Mellon Corp | 0.00% | Reduce -29.2% | 850,000 | $970K |
| Sei Investments Co. | 0.00% | No change | 322,000 | $367K |
| Loomis Sayles & Co. L P | 0.00% | No change | 3,570 | $186K |
| Oppenheimer Asset Management Inc. | 0.00% | Reduce -0.6% | 163,000 | $186K |
| Stephens Inc. | 0.00% | No change | 50,000 | $57K |
"% of holder's portfolio" is HALOZYME THERAPEUTICS IN (HALO 1 08/15/28)'s weight in each manager's 13F, not the share of Halozyme Therapeutics in (halo 1 08/15/28) the manager owns.